Home
Oligonucleotide Therapeutics and Delivery
11 September - 12 September 2023
Oligonucleotide Therapeutics and Delivery

This year SAE’s 3rd annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery and targeting and optimised delivery techniques for oligonucleotide-based therapies, in the hope to continue to drive forward the field of oligonucleotide drug development. Join us on the 11-12 September.

 The only event that will:

Showcase new representation and insights from the following big pharma companies, with a high level agenda focussing on driving industry advancement, whilst also offering benchmarking and networking opportunities for leading figures in the industry.
• Eli lilly
• Moderna
• BioNTech
• Alnylam Pharmaceuticals
• GSK
• Merck
• Servier
• AstraZeneca
• Roche
• Bayer

What’s different this year:

This year the conference will be chaired by two leaders in the field of oligonucleotide therapeutics and delivery: Joseph R. Martinelli, Executive Director, Genetic Medicine, Eli Lilly and Company & Edward Hennessy, Senior Director, Discovery Chemistry, Moderna.

 

FEATURED SPEAKERS

Beatriz Llamusi

Beatriz Llamusi

CSO, Arthex Biotech
Covadonga Paneda

Covadonga Paneda

Chief Development Officer, Altamira Therapeutics
David Tew

David Tew

Senior Scientific Director, GSK
Dhiman Ghosh

Dhiman Ghosh

Lab Head/Senior Principal Scientist, Sanofi
Edward Hennessy

Edward Hennessy

Senior Director, Discovery Chemistry, Moderna
Ekkehard Leberer

Ekkehard Leberer

Scientific Advisor, NEUWAY Pharma
John Stockley

John Stockley

Principal Scientist, Eurofins Biopharma Product Testing
Joseph Martinelli

Joseph Martinelli

Executive Director, Eli Lilly
Kaushik Thanki

Kaushik Thanki

Director Early-Stage Formulation Process Development, BioNTech SE
Lee Klein

Lee Klein

Principal Scientist, Merck & Co., Inc
Michael Keller

Michael Keller

Expert Scientist, Roche
Nagy Habib

Nagy Habib

Head of HBP Surgery, Co-Founder, Imperial College
Thierry Dorval

Thierry Dorval

Head of Data Sciences & Data Management, Institut de Recherches Servier
Thomas Frischmuth

Thomas Frischmuth

CEO, rnatics GmbH
Yaniv Erlich

Yaniv Erlich

CEO, Eleven Therapeutics

Beatriz Llamusi

CSO, Arthex Biotech
Beatriz Llamusi

Covadonga Paneda

Chief Development Officer, Altamira Therapeutics
Covadonga Paneda

Covadonga Pañeda, Ph.D. has over 15 years of experience in leadership and management of biotechnology companies. Before joining Altamira in April 2022, she spent seven years managing Sylentis’ R&D efforts, a clinical stage RNAi company, two years leading the translational activities of start-up companies Isquaemia Biotech and Mirnax Biosens; and most recently, she served as Director of Development at LiMM Therapeutics, a French neuroimmune biopharmaceutical company.
Dr. Pañeda holds a Ph.D. in Biochemistry and Molecular Biology from the Faculty of Medicine at Universidad Autónoma, Madrid, Spain, and a Master in Management of Biotechnology Companies awarded by Fundación Genoma España, Madrid, Spain.
 

David Tew

Senior Scientific Director, GSK
David Tew

Dhiman Ghosh

Lab Head/Senior Principal Scientist, Sanofi
Dhiman Ghosh
Dhiman Ghosh is a Senior Principal Scientist and Lab Head in the Precision Medicine and Computational Biology (PMCB) division at Sanofi, in Cambridge, MA. With core expertise in mass spectrometry and proteomics, biomarkers, and bioanalysis he is spearheading a variety of efforts in exploratory research space requiring singleshot global and targeted proteomics platform development. Dr. Ghosh received his Ph.D. in Biochemistry and Medical Genetics from the University of Manitoba, Canada for his research work on the elucidation of membrane proteomes of lymphoid and myeloid precursors by mass spectrometry. During his postdoctoral work at the Institute for Systems Biology in Seattle, WA with Dr. Leroy Hood, he developed integrated multidimensional omics-based analytical platform to query disease-perturbed networks that revealed the identity of several blood circulating proteins with potentials in disease diagnosis. Dhiman held positions both in academia and industry and is passionate about the implementation of novel tools and technologies to advance the understanding of biology and drug discovery.

Edward Hennessy

Senior Director, Discovery Chemistry, Moderna
Edward Hennessy

Ed Hennessy is Senior Director of Discovery Chemistry at Moderna, and leads the company’s internal chemistry efforts directed at the discovery of novel lipids for RNA delivery. He received a BA in chemistry at Northwestern University, followed by a Ph.D. in organic chemistry at MIT under Prof. Stephen Buchwald. He then worked as a medicinal chemist at AstraZeneca for over 12 years, contributing to and leading multiple programs culminating in several clinical candidates and one approved drug. Ed joined Moderna in early 2018, helping to lead research activities directed at optimizing mRNA delivery to different tissues and cell types.

Ekkehard Leberer

Scientific Advisor, NEUWAY Pharma
Ekkehard Leberer

Ekkehard serves as an independent life sciences consultant at ELBIOCON (www.elbiocon.com) with more than 30 years of experience in biotechnology and pharmaceutical industry. He headed research teams and held managerial positions at the Biotechnology Research Institute of the National Research Council (NRC) of Canada in Montreal and in Big Pharma at Hoechst Marion Roussel, Aventis and Sanofi in Martinsried/Munich and Hoechst/Frankfurt. He was educated in chemistry and molecular biology at the University of Konstanz (Ph.D. and Habilitation in biochemistry) and University of Toronto (PostDoc at the Banting and Best Department of Medical Research). He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.
His scientific and managerial activities included responsibilities in functional genomics, genetic engineering, biological sciences, pre-clinical and clinical development of various therapeutic modalities encompassing small molecule drugs and biopharmaceuticals (peptides, antibodies, oligonucleotides, and mRNAs), drug delivery, portfolio management, external innovation, alliance management and business strategies.
Ekkehard served as a member in Scientific Advisory Boards of several biotechnology companies, and he was the Head of the Supervisory Board of BioM, Munich (www.bio-m.org). He is a member in the life sciences consulting network NewGuide (www.newguide.net).
 

John Stockley

Principal Scientist, Eurofins Biopharma Product Testing
John Stockley

I am a Principal scientist at Eurofins BioPharma Product Testing in Ireland specialising in Oligonucleotides testing servcies. I graduated with honors bacherlors and PhD degrees in Biochemistry from University College Cork in Ireland. I have spent over 13 years in Cambridge UK, working at the Cambridge Stem Cell Institute, Astrazeneca and a spin out company at the Stevenage BioCatalyst. My expertise is in neuroscience and glia biology for central nervous system regeneration and rejuvenation.After trying small molecules, large molecules and stem-progenitor cells for brain repair I was converted to gene therapy approaches after getting involved with colleagues stunning work using AAVs and antisense oligonucleotides. My current scientific interests include oligonucleotide modifications for cell targeting, structural biology insights using AI and perfecting methods for drug substance and drug product assays.

Joseph Martinelli

Executive Director, Eli Lilly
Joseph Martinelli

Joe earned his B.S. in chemical engineering from the University of Wisconsin – Madison in 2002. From there, he moved to MIT and studied organic chemistry under the direction of Prof. Stephen L. Buchwald. After earning his Ph.D in 2007, Joe moved to Eli Lilly and Company as a Research Scientist in the group that is now Small Molecule Design and Development (SMDD). During his time in SMDD, Joe has worked on numerous projects, contributed to the commercialization of several assets, lead the Catalysis Lab. Joe moved to Cambridge MA and joined Lilly Genetic Medicine in early 2020. He is currently an Executive Director in Lilly Genetic Medicine and leads a team of talented chemists working on a variety of projects.

 

Kaushik Thanki

Director Early-Stage Formulation Process Development, BioNTech SE
Kaushik Thanki

Lee Klein

Principal Scientist, Merck & Co., Inc
Lee Klein

Lee obtained his Ph.D. in Analytical/Organic Chemistry at Indiana University in 2001 where he studied electrochemistry, photochemistry, EPR/ESR, and separations. He then spent 2 years teaching full time as an Adjunct Professor of Chemistry at Indiana University where he taught general chemistry, quantitative analysis, and chemical instrumentation. Lee joined Merck & Co., Inc. (West Point, PA) in 2003 and will be celebrating his 20th anniversary with the company this year. Lee has had a number of different roles at Merck focused on pre-clinical and early phase analytical development spanning small molecule, siRNA, and vaccine drug products including mRNA LNPs. Today Lee is a Principal Scientist supporting vaccine analytical development.

Michael Keller

Expert Scientist, Roche
Michael Keller

Michael Keller studied Chemistry & Biochemistry at the ETH Zürich from 1989-1994. The award of the ETHZ-Imperial College London exchange scholarship 1994 enabled him to pursue a MSC/DIC in Chemical Research at Imperial College London, before joining the Research group of Professor Manfred Mutter at the University of Lausanne where he carried out a PhD in Bioorganic Chemistry. After a year as lecturer at the same Institute, he joined Imperial College London Genetic Therapies Centre as Academic Visitor specializing in nonviral delivery systems for nucleic acids. He co-founded the Anglo/Japanese Biotech company IC-Vec Ltd. in 2002 developing novel cationic lipids and nanomedicines for siRNA delivery, before joining Novartis Pharma AG Basel to build up siRNA formulation in Technical Research & Development. He was awarded the Novartis Leading Scientist Award in 2009 for his work on siRNA delivery. In late 2017 he joined the Therapeutic Modality function at pRED/Hoffmann-La Roche Ltd. Basel to work on nucleic acid based medicines (NABM), with a particular focus on disruptive concepts to enable efficient delivery of nucleic acids to non-hepatic tissues.

Nagy Habib

Head of HBP Surgery, Co-Founder, Imperial College
Nagy Habib

Nagy is a founder and Head of R&D of MiNA Therapeutics and Head of Department of HPB Surgery at  Imperial College London. For over three decades he has been at the forefront of clinical research and clinical practice in cancer.
Currently, he is driving the development of an saRNA drug which is currently being trialed in patients with liver cancer in eight UK centres, and sites in Singapore and Taiwan (OUTREACH study, 

Clinical Trials.gov ID NCT02716012) and in a second trial in patients with solid tumours (TIMEPOINT  study, ClinicalTrials.gov ID NCT 04105335) in the UK, USA, Europe, Singapore and Taiwan.

Thierry Dorval

Head of Data Sciences & Data Management, Institut de Recherches Servier
Thierry Dorval

Thierry Dorval received a B.S. degree in theoretical physic and obtained a Ph.D. in image processing and artificial intelligence at Pierre & Marie Curie University, Paris, France. He then joined the Institut Pasteur Korea in 2005 first as researcher in biological image analysis then as a group leader specialized in High Content Screening applied to cellular differentiation as well as toxicity prediction. In 2012 he joined AstraZeneca, UK, where he was leading the Image and Data Analytics team. His activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screens.
In 2015 he joined Servier, France, first as leader of the High Content Screening group within CentEX CPCB and then as Head of Data Science Lab, working on phenotypic approaches to improve drug discovery pipeline efficiency using high content and machine learning strategies.
 

Thomas Frischmuth

CEO, rnatics GmbH
Thomas Frischmuth

Since more than 30 years Thomas Frischmuth is actively working in the life science field as researcher (university as well as industry, more than 70 publications and several patents), advisor and consultant (companies and public organization) and in management position.

The research activities ranges from chemical synthesis (small scale and large scale), chemical analyses, molecular and cell biology, biotech synthesis (small and large scale), diagnostic, medical device (heart support systems), agriculture and drug to treatment development.

Thomas developed and evaluated 6 drugs and vaccines pre-clinically and brought 4 of them into clinical evaluation studies. One drug is marketed for cancer treatment.

In 2003, Thomas founded his own private venture fund company (Gradus Venture GmbH) and since then has co-founded and invested of today in 6 companies.
 

Yaniv Erlich

CEO, Eleven Therapeutics
Yaniv Erlich

Dr. Yaniv Erlich is the co-founder and CEO of Eleven Therapeutics. Prior to this position, he was the CSO of MyHeritage, a consumer genomics company (acquired by Francisco Partners), an Associate Professor of Computer Science at Columbia University and a Principal Investigator at the Whitehead Institute, MIT. Dr. Erlich received his bachelor’s degree from Tel-Aviv University, Israel (2006) and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory (2010). Dr. Erlich’s research interests are computational human genetics. Dr. Erlich is a TEDMED speaker (2018), the recipient of DARPA’s Young Faculty Award (2017), the Burroughs Wellcome Career Award (2013), Harold M. Weintraub award (2010), the IEEE/ACM-CS HPC award (2008), and he was selected as one of 2010 Tomorrow’s PIs team of Genome Technology.

sponsors

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Joseph Martinelli, Executive Director, Eli Lilly

Edward Hennessy, Senior Director, Discovery Chemistry, Moderna

clock

9:10

Genetic medicine: state of the art, frontiers and current research

Joseph Martinelli, Executive Director, Eli Lilly

  • Addressing key challenges at the forefront of the next generation of genetic medicines
  • The role of Nucleic acid innovation in the development of RNA therapeutics
  • Exploring delivery innovation as a crucial component in the advancement of RNA therapies
  • clock

    9:50

    Introduction to RNA activation to restore cell function

    Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College

  • RNA activation for treatment of acquired and rare genetic diseases
  • RNA aptamers for oligonucleotide delivery
  • Discussion of increasing oligonucleotide drugs and why this matters
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Implications of Oligonucleotide structure in method development

    John Stockley, Principal Scientist, Eurofins Biopharma Product Testing

  • Oligonucleotides (ONs) can form complex structures depending on their sequence and their environment
  • ONs are modelled using RNA folding software
  • ONs with open structures are easily resolved by HPLC compared to ONs with loops
  • ONs with loops can dimerise, implications for efficacy and off target effects
     
  • clock

    11:40

    OligoPhore and SemaPhore for extrahepatic delivery of therapeutic RNA

    Covadonga Paneda, Chief Development Officer, Altamira Therapeutics

  •  Description of OligoPhore and SemaPhore platforms for delivery therapeutic RNA
  • Rapid and extensive pH-dependent release of RNA from endosomal resulting in effective delivery into cells
  • Distribution of therapeutic RNA into extrahepatic tissues
  • Examples of effective RNA activity in animal models of disease
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    xRNA: next generation mRNA therapeutics

    Yaniv Erlich, CEO, Eleven Therapeutics

  • xRNA utilizes non-canonical building blocks to boost the duration of effect of mRNA technologies
  • Our in-vitro and in-vivo experiments show the superiority of this technology over regular mRNA
  • We are in the process of building a massively parallel assay to deep-learn the SAR of xRNA molecules
  •  

    clock

    14:00

    Development of a lipophilic-conjugated antimiR to treat Myotonic Dystrophy type 1 (DM1)

    Beatriz Llamusi

    Beatriz Llamusi, CSO, Arthex Biotech

  • DM1 is a rare disease with a complex but well understood pathophysiology which leads to reduced availability of regulatory MBNL proteins due to an expansion of non-coding CTG repeats in the DMPK gene
  • Arthex has developed a lipophilic-conjugated antimir-23b oligo (ATX-01), that acts on both MBNL protein and DMPK mRNA  levels, alleviating functional and molecular signs of the disease in human cell and animal models
  • ATX-01 is remarkably safe and well-tolerated in relevant toxicology species including NHP, and the therapeutic window supports testing of ascending doses in human patients.
  • Arthex will initiate a multinational PhI/IIa clinical trial of patients with DM1, later this year

     

  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Manufacturing therapeutic oligonucleotides - the challenges of scale, cost and sustainability

    David Tew

    David Tew, Senior Scientific Director, GSK

  • Solid phase vs liquid phase methods
  • New chemistries for oligonucleotide synthesis
  • The use of enzymes in oligonucleotide synthesis
  • Thoughts on how these new methods will help to address cost and sustainability issues
  • clock

    15:50

    Chairman’s Closing Remarks and Close of Day One

    Joseph Martinelli, Executive Director, Eli Lilly

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Joseph Martinelli, Executive Director, Eli Lilly

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna

    clock

    9:10

    Discovery of novel amino lipids for mRNA delivery

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna

  •  An introduction to lipid nanoparticles (LNPs) for the delivery of nucleic acids, with a focus on the role of  the amino lipid component
  • Medicinal chemistry strategies for optimizing lipid/LNP physical properties, pharmacokinetics, and biological performance
  • Utilization of computational modelling to guide the design of  improved delivery vehicles for mRNA
  • clock

    9:50

    Data Driven Optimization of Oligonucleotide Sequence Design

    Thierry Dorval, Head of Data Sciences & Data Management, Institut de Recherches Servier

  •  Optimising drug discovery using computational and knowledge graph approaches
  • Case Studies from Servier’s ASOS design approach
  • Ensuring adverse effect identifi cation using AI approaches
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Challenges and opportunities in target validation and pathway exploration through mass spectrometry-based proteomics

    Dhiman Ghosh, Lab Head/Senior Principal Scientist, Sanofi

  • Key challenges in drug discovery for the characterization of gene therapy products by mass spectrometry-based global and targeted proteomics
  • Case study involving global proteomic strategy for evaluating diseasealtered pathways and targets in ALS using h-iPSC derived cells
  • Targeted proteomics application in the identifi cation and quantification of AAV delivered Arylsulfatase A (ARSA) to align with future effi cacy assessment in NHP brain
  • clock

    11:40

    Targeting of RNA beyond LNP

    Thomas Frischmuth, CEO, rnatics GmbH

  •  Conjugation of ligands to RNA species
  • Ligands targeting in particular sugar receptors
  • RNA species of LNA, siRNA and mRNA origin
  • Targeting of lung makrophages
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    PANEL DISCUSSION: Reviewing Oligonucleotide therapeutics as the next generation of genetic medicines

  •  Discussing current drug like properties of oligo-based medicines: Cargo (e.g., properties of siRNA) vs carriers (e.g., properties of LNPs)
  • Dissecting the challenges associated with targeted delivery of oligonucleotides
  • Understanding the future direction of ASOs and oligo-based based drugs, with a focus on emerging, novel oligonucleotides
  • Kaushik Thanki

    Kaushik Thanki, Director Early-Stage Formulation Process Development, BioNTech SE

    Thierry Dorval, Head of Data Sciences & Data Management, Institut de Recherches Servier

    clock

    14:00

    Advanced Analytical Characterization of mRNA LNPs

    Lee Klein, Principal Scientist, Merck & Co., Inc

  • Methods to characterize LNP surfaces including:
  • PEG lipid surface saturation
  • PZC for charge distribution
  • Surface binding
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Protein-based nanocapsules for therapeutic RNA delivery to the brain

    Ekkehard Leberer, Scientific Advisor, NEUWAY Pharma

  •  The presentation will describe the generation and the use of protein-based nanocapsules to deliver a broad range of therapeutic RNAs across the blood-brain barrier.
  • The therapeutic potential of this delivery technology will be illustrated for the treatment of monogenetic CNS disorders such as metachromatic leukodystrophy (MLD), a lysosomal storage
    disease
  • clock

    15:50

    Chairman’s Closing Remarks and Close of Day Two

    Joseph Martinelli, Executive Director, Eli Lilly

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna


    CSO
    Arthex Biotech
    Chief Development Officer
    Altamira Therapeutics
    Senior Scientific Director
    GSK
    Lab Head/Senior Principal Scientist
    Sanofi
    Senior Director, Discovery Chemistry
    Moderna
    Scientific Advisor
    NEUWAY Pharma
    Principal Scientist
    Eurofins Biopharma Product Testing
    Executive Director
    Eli Lilly
    Director Early-Stage Formulation Process Development
    BioNTech SE
    Principal Scientist
    Merck & Co., Inc
    Expert Scientist
    Roche
    Head of HBP Surgery, Co-Founder
    Imperial College
    Head of Data Sciences & Data Management
    Institut de Recherches Servier
    CEO
    rnatics GmbH
    CEO
    Eleven Therapeutics

    Sponsors

    Exhibitors

    Speaker Presentation

    Download

    Speaker Presentation

    Download

    Past Attendee List

    Download

    Sponsors


    Cytiva

    Sponsors
    https://www.cytivalifesciences.com/en/us

    From pioneering research to innovative vaccines and therapies, our customers are transforming medicine and saving lives. Now, Cytiva and Pall Life Sciences are joining forces to best support this vital work. As one company, we offer the tools, depth, breadth, and scale the life science community needs to work better, faster, and smarter. Let’s advance the next generation of therapeutics from discovery to delivery, together.


    Eurofins BioPharma

    Sponsors
    https://www.eurofins.ie/biopharma-services/

    Eurofins BioPharma Product Testing, part of Eurofins Scientific, has a network of 44 facilities in 22 countries which delivers the world’s most comprehensive scope of harmonised GMP testing services and seamless regulatory acceptance.

    Our services range from physical, chemical and microbiological testing of pharmaceutical raw materials to finished dosage forms, thereby covering release, stability and validation for small and large molecule drug products, and medical devices. We have proven expertise in Oligonucleotides, Biologics, Gene Therapy, Chemistry, Process Control, Molecular Cell Biology, Bioassay, Raw Materials and Microbiology with continuous investment in these areas.

    Our commitment to sustainability and environmental protection is demonstrated by our ISO 14001 certification – achieved in March 2022 across all sites in Europe.


    Exhibitors


    ChemGenes

    Exhibitors
    https://www.chemgenes.com/

    ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. In addition, ChemGenes is expanding its custom oligonucleotide synthesis department specializing in the manufacture of ASOs, siRNA, gRNA, gapmers, aptamers, DNA based probes, and superior quality beads for Single Cell mRNA sequencing applications using Drop-Seq, Slide-seq, and Seq-Well methods. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.



    CordenPharma

    Exhibitors
    https://cordenpharma.com/

    CordenPharma is your full-service CDMO in the manufacturing of APIs, Excipients, Drug Products and Packaging. Through a network of cGMP facilities organized under six technology platforms – Peptides, Oligonucleotides, Lipids, & Carbohydrates – Injectables - Highly Potent & Oncology - Small Molecules - CordenPharma experts translate complex ideas into high-value products.

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.